Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNECTION: Phase 3 double-blind placebo-controlled study of oral Dimebon in mild-to-moderate Alzheimer's disease
2008-000095-25Phase 3Completed
- Sponsor
- Medivation
- Start
- Jun 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Dimebon 20 mg TID with Placebo (2 arms). Primary endpoint: Primary: Change from baseline in ADAS-cog at Week 26 (Dimebon 20 mg TID vs placebo). Started Jun 2008; status: completed.
02
Drugs
latrepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2008-000095-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000095-25.